{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:00:41Z","timestamp":1761292841340,"version":"build-2065373602"},"reference-count":44,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,8,25]],"date-time":"2011-08-25T00:00:00Z","timestamp":1314230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>New treatment strategies for locally advanced head and neck squamous cell carcinoma combine induction chemotherapy and chemoradiation. Identifying the predictors of outcome in sequentially treated patients is critical for focusing therapeutic research. In this analysis, the authors evaluated human papillomavirus type 16 (HPV\u201016) status and the expression levels of a defined set of biomarkers to identify predictors of response to this treatment modality.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>In total, 114 patients with oropharyngeal cancer (OPC) who were treated on the TAX 324 trial (cisplatin and fluorouracil with or without docetaxel in patients with locally advanced head and neck squamous cell carcinoma) had pretreatment biopsy specimens that were evaluable for HPV\u201016 DNA and immunohistochemical expression of the following biomarkers: beta\u2010tubulin II (\u03b2T\u2010II), glutathione S\u2010transferase (GST\u2010\u03c0), p53, and B\u2010cell lymphoma 2 (Bcl\u20102). Patients were categorized into risk groups based on their HPV status and biomarker expression levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Patients with high\u2010risk OPC were defined by HPV\u2010negative status and either elevated expression of \u03b2T\u2010II or levels of at least 2 of the other 3 adverse markers (elevated GST\u2010\u03c0, elevated p53, or low Bcl\u20102). All other HPV\u2010negative patients were categorized as moderate risk. In total, 55 patients were HPV\u2010positive, and 59 patients were HPV\u2010negative, with 34 were categorized as high risk and 25 categorized as moderate risk. The median survival for HPV\u2010positive patients was not reached. The median survival was 44.2 months for moderate\u2010risk patients (95% confidence interval, 20.9 months to not reached) and 12.1 months for high\u2010risk patients (95% confidence interval, 7.5\u201019.7 months). The 24\u2010month survival rate was 89% for HPV\u2010positive patients, 67% for moderate\u2010risk patients, and 29% for high\u2010risk patients (<jats:italic>P<\/jats:italic> &lt; .0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The molecular data set in this study readily differentiated between 2 distinct groups of patients with locally advanced, HPV\u2010negative OPC. This risk\u2010stratification strategy may serve as a guide for treatment selection. Cancer 2012;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26485","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T22:35:38Z","timestamp":1314830138000},"page":"1811-1817","source":"Crossref","is-referenced-by-count":27,"title":["Novel biomarker panel predicts prognosis in human papillomavirus\u2010negative oropharyngeal cancer"],"prefix":"10.1002","volume":"118","author":[{"given":"Yin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall R.","family":"Posner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Schumaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Nikitakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Goloubeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changwan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Sarlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,25]]},"reference":[{"volume-title":"Cancer Statistics 2009 Presentation","year":"2009","author":"American Cancer Society","key":"e_1_2_6_2_2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.04.014"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.265"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1512"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.709"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0551"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2005.08.001"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.09.001"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22851"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn011"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912217"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20998"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1713"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4525"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0953"},{"key":"e_1_2_6_19_2","first-page":"4097","article-title":"Prognostic value of p53, glutathione S\u2010transferase pi, and thymidylate synthase for neoadjuvant cisplatin\u2010based chemotherapy in head and neck cancer","volume":"5","author":"Shiga H","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_20_2","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred DC","year":"1998","journal-title":"Mod Pathol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2005.030814.x"},{"issue":"15","key":"e_1_2_6_22_2","article-title":"Oropharynx cancer (OPC) in TAX 324: human papillomavirus (HPV) and survival [abstract]","volume":"28","author":"Posner MR","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0149"},{"key":"e_1_2_6_24_2","first-page":"1859","article-title":"Glutathione S\u2010transferase expression predicts response to cisplatin\u2010based chemotherapy in head and neck cancer","volume":"2","author":"Nishimura T","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_25_2","first-page":"8097","article-title":"Glutathione\u2010S\u2010transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors","volume":"63","author":"Cullen KJ","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra001375"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.385"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1465"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4170"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(01)00301-2"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10960"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1291"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6136"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22355"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7662"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7597"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2008.11.025"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/00016480310016893"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9"},{"key":"e_1_2_6_41_2","first-page":"355","article-title":"Radiosensitivity of tumor cells. Oncogenes and apoptosis","volume":"44","author":"Peltenburg LT","year":"2000","journal-title":"Q J Nuc Med"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1759"},{"key":"e_1_2_6_43_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ijc.24842","article-title":"Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of treatment modality?","volume":"126","author":"Fischer CA","year":"2009","journal-title":"Int J Cancer"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/000348940911800509"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.18.1541"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26485","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:22:28Z","timestamp":1760304148000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26485"}},"subtitle":["An analysis of the TAX 324 trial"],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/cncr.26485"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26485","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}